| 0.012 -0.007 (-36.84%) | 12-18 12:51 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Bellerophon Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company primarily focused on developing novel therapies for various cardiopulmonary conditions. Its flagship product is INOpulse, a proprietary platform designed to deliver pulsatile nitric oxide, specifically targeting pulmonary hypertension (PH). The company is actively advancing the development of INOpulse across multiple indications: Currently, INOpulse is undergoing a Phase 3 clinical trial for pulmonary hypertension linked to fibrotic interstitial lung disease. It has successfully completed a Phase 2a trial for pulmonary hypertension tied to chronic obstructive pulmonary disease. Furthermore, a Phase 2 dose escalation stage has concluded for pulmonary hypertension associated with sarcoidosis. The company is also exploring INOpulse's potential for chronic thromboembolic pulmonary hypertension and PH stemming from high altitude sickness. Founded in 2009, the enterprise, originally known as Ikaria Development LLC, adopted the Bellerophon Therapeutics, Inc. name in January 2014. Its corporate headquarters are situated in Warren, New Jersey.
Mon, 04 Mar 2024
Bellerophon Shareholders Vote to Dissolve Amid Board Resignations - TipRanks
Wed, 16 Aug 2023
Crispin Teufel Net Worth (2026) - GuruFocus
Thu, 03 Nov 2022
Matthew S. Holt Net Worth (2026) - GuruFocus
Wed, 26 May 2021
Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors - citybiz
Mon, 01 Feb 2021
7 notable pulmonary fibrosis research efforts - drugdiscoverytrends.com
Thu, 03 Sep 2015
Bellerophon to Present in Upcoming Investor Conferences - globenewswire.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|